Many children with melanoma do not meet ABCDE criteria

July 19, 2013
Many children with melanoma do not meet ABCDE criteria
A considerable proportion of children with melanoma do not present with conventional melanoma detection criteria (asymmetry, border irregularity, color variegation, diameter > 6 mm, and evolution), according to a study published in the June issue of the Journal of the American Academy of Dermatology.

(HealthDay)—A considerable proportion of children with melanoma do not present with conventional melanoma detection criteria (asymmetry, border irregularity, color variegation, diameter >6 mm, and evolution [ABCDE]), according to a study published in the June issue of the Journal of the American Academy of Dermatology.

Kelly M. Cordoro, M.D., from the University of California in San Francisco, and colleagues conducted a involving 60 children with a diagnosis of melanoma and 10 children with ambiguous melanocytic tumors treated as melanoma, diagnosed before age 20 from 1984 to 2009. The patients were categorized by age: 0 to 10 years (19 patients, group A) and 11 to 19 years (51 patients, group B).

The researchers found that 60 and 40 percent of groups A and B, respectively, did not present with conventional ABCDE criteria. The most common features included amelanosis, bleeding, "bumps," uniform color, variable diameter, and de novo development. Significant between-group variation was observed in histopathological subtypes. Forty-four percent were considered histopathologically unclassifiable according to current melanoma subtypes. In groups A and B, 92 and 46 percent of patients, respectively, had stage IIA disease or higher (P = 0.05). One patient in group A and nine in group B died; 70 percent of these cases had amelanotic lesions and 60 percent had one or more major . Metastasis was predicted with Breslow thickness (adjusted odds ratio, 12.8).

"Additional ABCD detection criteria (Amelanotic; Bleeding, Bump; Color uniformity; De novo, any Diameter) used together with conventional ABCDE criteria may facilitate earlier recognition and treatment of in children," write the authors.

Explore further: Negative pigment network able to distinguish melanoma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Negative pigment network able to distinguish melanoma

October 25, 2012
(HealthDay)—Negative pigment network (NPN) can be used to distinguish melanoma from Spitz nevus and other benign lesions, according to a study published online Oct. 11 in the Journal of the American Academy of Dermatology.

Risk of second primary melanoma up in pediatric patients

June 28, 2012
(HealthDay) -- Pediatric patients diagnosed with an invasive cutaneous melanoma have nearly double the relative risk of developing a subsequent primary melanoma, compared with adults, according to a study published online ...

Surgeons report melanoma recurs after 10 years in more than 6 percent of patients

June 27, 2013
Recurrence of melanoma skin cancer 10 or more years after initial treatment is more common than previously thought, occurring in more than one in 20 patients. However, according to a new study, these patients tend to live ...

Pediatric melanomas are increasing two percent a year

April 16, 2013
(HealthDay)—The incidence of pediatric melanoma has increased by about 2 percent per year, and this incidence trend is influenced by gender, age, and stage at diagnosis, primary site, and ultraviolet (UV)-B exposure, according ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.